Importance of (antibody-dependent) complement-mediated serum killing in protection against Bordetella pertussis

References

• Black RE, Cousens S, Johnson HL, et al. Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010;375(9730):1969-87
   PubMed Web of Science ®Google Scholar
• Cherry JD. Why do pertussis vaccines fail? Pediatrics 2012;129(5):968-70
   PubMed Web of Science ®Google Scholar
• Goodnow RA. Biology of Bordetella bronchiseptica. Microbiol Rev 1980;44(4):722-38
   PubMedGoogle Scholar
• van der Zee A, Mooi F, Van Embden J, Musser J. Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences. J Bacteriol 1997;179(21):6609-17
   PubMedGoogle Scholar
• Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 2012;5(5):485-500
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-4
   PubMed Web of Science ®Google Scholar
• Pangburn MK. The alternative pathway of complement. Springer Semin Immunopathol 1984;7:163-92
   PubMed Web of Science ®Google Scholar
• Fujita T. Evolution of the lectin–complement pathway and its role in innate immunity. Nat Rev Immunol 2002;2:346-53
   PubMed Web of Science ®Google Scholar
• Degn SE, Thiel S, Jensenius JC. New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology 2007;212(4-5):301-11
   PubMedGoogle Scholar
• Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006;176(3):1305-10
   PubMed Web of Science ®Google Scholar
• Czermak BJ, Friedl HP, Ward PA. Role and regulation of chemokines in rodent models of lung inflammation. ILAR J 1999;40(4):163-6
   PubMedGoogle Scholar
• Bosmann M, Ward PA. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol 2012;946:147-59
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Hallström T, Riesbeck K. Human complement control and complement evasion by pathogenic microbes – tipping the balance. Mol Immunol 2013;56(3):152-60
   PubMed Web of Science ®Google Scholar
• Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol 2008;6(2):132-42
   PubMed Web of Science ®Google Scholar
• Joiner K, Brown E, Hammer C, et al. Studies on the mechanism of bacterial resistance to complement-mediated killing. III. C5b-9 deposits stably on rough and type 7 S. Pneumoniae without causing bacterial killing. J Immunol 1983;130(2):845-9
   PubMedGoogle Scholar
• DeLeo FR. Modulation of phagocyte apoptosis by bacterial pathogens. Apoptosis 2004;9(4):399-413
   PubMedGoogle Scholar
• De Gouw D, Diavatopoulos DA, Bootsma HJ, et al. Pertussis: a matter of immune modulation. FEMS Microbiol Rev 2011;35(3):441-74
   PubMed Web of Science ®Google Scholar
• Weingart CL, Weiss AA. Bordetella pertussis virulence factors affect phagocytosis by human neutrophils. Infect Immun 2000;68(3):1735-9
   PubMed Web of Science ®Google Scholar
• Berner R, Krause MF, Gordjani N, et al. Hemolytic uremic syndrome due to an altered factor H triggered by neonatal pertussis. Pediatr Nephrol 2002;17(3):190-2
   PubMedGoogle Scholar
• Caprioli J, Bettinaglio P, Zipfel PF, et al. Italian Registry of Familial and Recurrent HUS/TTP. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001;12(2):297-307
   PubMedGoogle Scholar
• Pela I, Seracini D, Caprioli A, et al. Hemolytic uremic syndrome in an infant following Bordetella pertussis infection. Eur J Clin Microbiol Infect Dis 2006;25(8):515-17
   PubMedGoogle Scholar
• Chaturvedi S, Licht C, Langlois V. Hemolytic uremic syndrome caused by Bordetella pertussis infection. Pediatr Nephrol 2010;25(7):1361-4
   PubMedGoogle Scholar
• Kurvers RA, Westra D, van Heijst AF, et al. Severe infantile Bordetella pertussis pneumonia in monozygotic twins with a congenital C3 deficiency. Eur J Pediatr 2013;172(8):1125-9
   PubMedGoogle Scholar
• Pishko EJ, Kirimanjeswara GS, Pilione MR, et al. Antibody-mediated bacterial clearance from the lower respiratory tract of mice requires complement component C3. Eur J Immunol 2004;34(1):184-93
   PubMedGoogle Scholar
• Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003;37(11):1496-505
   PubMed Web of Science ®Google Scholar
• Gröndahl-Yli-Hannuksela K, Viander M, Mertsola J, He Q. Increased risk of pertussis in adult patients with mannose-binding lectin deficiency. APMIS 2013;121(4):311-15
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17(7):1055-65
   PubMed Web of Science ®Google Scholar
• Rodriguez ME, Hellwig SM, Hozbor DF, et al. Fc receptor-mediated immunity against Bordetella pertussis. J Immunol 2001;167(11):6545-51
   PubMed Web of Science ®Google Scholar
• Harvill ET, Preston A, Cotter PA, et al. Multiple roles for Bordetella lipopolysaccharide molecules during respiratory tract infection. Infect Immun 2000;68(12):6720-8
   PubMedGoogle Scholar
• Hellwig SM, van Oirschot HF, Hazenbos WL, et al. Targeting to Fc gamma receptors, but not CR3 (CD11b/CD18), increases clearance of Bordetella pertussis. J Infect Dis 2001;183(6):871-9
   PubMed Web of Science ®Google Scholar
• Berton G, Laudanna C, Sorio C, Rossi F. Generation of signals activating neutrophil functions by leukocyte integrins: LFA-1 and gp150/95, but not CR3, are able to stimulate the respiratory burst of human neutrophils. J Cell Biol 1992;116(4):1007-17
   PubMedGoogle Scholar
• Saukkonen K, Cabellos C, Burroughs M, et al. Integrin-mediated localization of Bordetella pertussis within macrophages: role in pulmonary colonization. J Exp Med 1991;173(5):1143-9
   PubMed Web of Science ®Google Scholar
• Rautemaa R, Meri S. Complement-resistance mechanisms of bacteria. Microbes Infect 1999;1(10):785-94
   PubMed Web of Science ®Google Scholar
• Lerouge I, Vanderleyden J. O-antigen structural variation: mechanisms and possible roles in animal/plant-microbe interactions. FEMS Microbiol Rev 2002;26(1):17-47
   PubMed Web of Science ®Google Scholar
• Reeves P. Role of O-antigen variation in the immune response. Trends Microbiol 1995;3(10):381-6
   PubMedGoogle Scholar
• MacLennan CA, Gilchrist JJ, Gordon MA, et al. Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science 2010;328(5977):508-12
   PubMedGoogle Scholar
• Caroff M, Chaby R, Karibian D, et al. Variations in the carbohydrate regions of Bordetella pertussis lipopolysaccharides: electrophoretic, serological, and structural features. J Bacteriol 1990;172(2):1121-8
   PubMed Web of Science ®Google Scholar
• Caroff M, Brisson J, Martin A, Karibian D. Structure of the Bordetella pertussis 1414 endotoxin. FEBS Lett 2000;477(1-2):8-14
   PubMed Web of Science ®Google Scholar
• Allen AG, Thomas RM, Cadisch JT, Maskell DJ. Molecular and functional analysis of the lipopolysaccharide biosynthesis locus wlb from Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Mol Microbiol 1998;29(1):27-38
   PubMedGoogle Scholar
• Weiss AA, Mobberley PS, Fernandez RC, Mink CM. Characterization of human bactericidal antibodies to Bordetella pertussis. Infect Immun 1999;67(3):1424-31
   PubMed Web of Science ®Google Scholar
• Caroff M, Aussel L, Zarrouk H, et al. Structural variability and originality of the Bordetella endotoxins. J Endotoxin Res 2001;7(1):63-8
   PubMedGoogle Scholar
• Preston A, Petersen BO, Duus JØ, et al. Complete structures of Bordetella bronchiseptica and Bordetella parapertussis lipopolysaccharides. J Biol Chem 2006;281(26):18135-44
   PubMed Web of Science ®Google Scholar
• Preston A, Allen AG, Cadisch J, et al. Genetic basis for lipopolysaccharide O-antigen biosynthesis in bordetellae. Infect Immun 1999;67(8):3763-7
   PubMedGoogle Scholar
• Burns VC, Pishko EJ, Preston A, et al. Role of Bordetella O antigen in respiratory tract infection. Infect Immun 2003;71(1):86-94
   PubMedGoogle Scholar
• Byrd DW, Roop RM, Veit HP, Schurig GG. Serum sensitivity and lipopolysaccharide characteristics in Bordetella bronchiseptica, B. pertussis and B. parapertussis. J Med Microbiol 1991;34(3):159-65
   PubMedGoogle Scholar
• Rambow AA, Fernandez RC, Weiss AA. Characterization of BrkA expression in Bordetella bronchiseptica. Infect Immun 1998;66(8):3978-80
   PubMed Web of Science ®Google Scholar
• Goebel EM, Wolfe DN, Elder K, et al. O antigen protects Bordetella parapertussis from complement. Infect Immun 2008;76(4):1774-80
   PubMed Web of Science ®Google Scholar
• Fernandez RC, Weiss AA. Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infect Immun 1994;62(11):4727-38
   PubMed Web of Science ®Google Scholar
• Barnes MG, Weiss AA. Activation of the complement cascade by Bordetella pertussis. FEMS Microbiol Lett 2003;220(2):271-5
   PubMed Web of Science ®Google Scholar
• Neo Y, Li R, Howe J, et al. Evidence for an intact polysaccharide capsule in Bordetella pertussis. Microbes Infect 2010;12(3):238-45
   PubMedGoogle Scholar
• Amdahl H, Jarva H, Haanperä M, et al. Interactions between Bordetella pertussis and the complement inhibitor factor H. Mol Immunol 2011;48(4):697-705
   PubMed Web of Science ®Google Scholar
• Fernandez RC, Weiss AA. Serum resistance in bvg-regulated mutants of Bordetella pertussis. FEMS Microbiol Lett 1998;163(1):57-63
   PubMed Web of Science ®Google Scholar
• Barnes MG, Weiss AA. Growth phase influences complement resistance of Bordetella pertussis. Infect Immun 2002;70(1):403-6
   PubMedGoogle Scholar
• Pishko EJ, Betting DJ, Hutter CS, Harvill ET. Bordetella pertussis acquires resistance to complement-mediated killing in vivo. Infect Immun 2003;71(9):4936-42
   PubMedGoogle Scholar
• Elder KD, Harvill ET. Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract. Infect Immun 2004;72(10):5919-24
   PubMedGoogle Scholar
• Stefanelli P, Sanguinetti M, Fazio C, et al. Differential in vitro expression of the brkA gene in Bordetella pertussis and Bordetella parapertussis clinical isolates. J Clin Microbiol 2006;44(9):3397-400
   PubMed Web of Science ®Google Scholar
• Weyrich LS, Feaga HA, Park J, et al. Resident microbiota affect Bordetella pertussis infectious dose and host specificity. J Infect Dis 2014;209(6):913-21
   PubMedGoogle Scholar
• Schaeffer LM, McCormack FX, Wu H, Weiss AA. Bordetella pertussis lipopolysaccharide resists the bactericidal effects of pulmonary surfactant protein A. J Immunol 2004;173(3):1959-65
   PubMed Web of Science ®Google Scholar
• Schaeffer LM, McCormack FX, Wu H, Weiss AA. Interactions of pulmonary collectins with Bordetella bronchiseptica and Bordetella pertussis lipopolysaccharide elucidate the structural basis of their antimicrobial activities. Infect Immun 2004;72(12):7124-30
   PubMed Web of Science ®Google Scholar
• Harper M, Boyce JD, Adler B. The key surface components of Pasteurella multocida: capsule and lipopolysaccharide. Curr Top Microbiol Immunol 2012;361:39-51
   PubMedGoogle Scholar
• Hallström T, Riesbeck K. Haemophilus influenzae and the complement system. Trends Microbiol 2010;18(6):258-65
   PubMed Web of Science ®Google Scholar
• Kugelberg E, Gollan B, Tang CM. Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing. Vaccine 2008;26(Suppl 8):I34-9
   PubMedGoogle Scholar
• Stevens P, Young LS, Adamu S. Opsonization of various capsular (K) E. coli by the alternative complement pathway. Immunology 1983;50(3):497-502
   PubMedGoogle Scholar
• Allen PM, Roberts I, Boulnois GJ, et al. Contribution of capsular polysaccharide and surface properties to virulence of Escherichia coli K1. Infect Immun 1987;55(11):2662-8
   PubMed Web of Science ®Google Scholar
• Cross AS, Kim KS, Wright DC, et al. Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli. Infect Dis 1986;154(3):497-503
   Google Scholar
• Sloan GP, Love CF, Sukumar N, et al. The Bordetella Bps polysaccharide is critical for biofilm development in the mouse respiratory tract. J Bacteriol 2007;189(22):8270-6
   PubMedGoogle Scholar
• Parise G, Mishra M, Itoh Y, et al. Role of a putative polysaccharide locus in Bordetella biofilm development. J Bacteriol 2007;189(3):750-60
   PubMed Web of Science ®Google Scholar
• Conover MS, Sloan GP, Love CF, et al. The Bps polysaccharide of Bordetella pertussis promotes colonization and biofilm formation in the nose by functioning as an adhesin. Mol Microbiol 2010;77(6):1439-55
   PubMed Web of Science ®Google Scholar
• Ganguly T, Johnson JB, Kock ND, et al. The Bordetella pertussis Bps polysaccharide enhances lung colonization by conferring protection from complement-mediated killing. Cell Microbiol 2014;16(7):1105-18
   PubMed Web of Science ®Google Scholar
• Weiss AA, Goodwin MS. Lethal infection by Bordetella pertussis mutants in the infant mouse model. Infect Immun 1989;57(12):3757-64
   PubMed Web of Science ®Google Scholar
• Barnes MG, Weiss AA. BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition. Infect Immun 2001;69(5):3067-72
   PubMed Web of Science ®Google Scholar
• Marr N, Shah NR, Lee R, et al. Bordetella pertussis autotransporter Vag8 binds human C1 esterase inhibitor and confers serum resistance. PLoS One 2011;6(6):e20585
   PubMed Web of Science ®Google Scholar
• Finn TM, Amsbaugh DF. Vag8, a Bordetella pertussis bvg-regulated protein. Infect Immun 1998;66(8):3985-9
   PubMedGoogle Scholar
• Noofeli M, Bokhari H, Blackburn P, et al. BapC autotransporter protein is a virulence determinant of Bordetella pertussis. Microb Pathog 2011;51(3):169-77
   PubMed Web of Science ®Google Scholar
• Benz I, Schmidt MA. Structures and functions of autotransporter proteins in microbial pathogens. Int J Med Microbiol 2011;301(6):461-8
   PubMedGoogle Scholar
• Singh B, Su YC, Al-Jubair T, et al. A Fine-Tuned Interaction between Trimeric Autotransporter Haemophilus Surface Fibrils and Vitronectin Leads to Serum Resistance and Adherence to Respiratory Epithelial Cells. Infect Immun 2014;82(6):2378-89
   PubMed Web of Science ®Google Scholar
• Del Tordello E, Vacca I, Ram S, et al. Neisseria meningitidis NalP cleaves human complement C3, facilitating degradation of C3b and survival in human serum. Proc Natl Acad Sci USA 2014;111(1):427-32
   PubMedGoogle Scholar
• Ruiz-Ranwez V, Posadas DM, Estein SM, et al. The BtaF trimeric autotransporter of Brucella suis is involved in attachment to various surfaces, resistance to serum and virulence. PLoS One 2013;8(11):e79770
   PubMedGoogle Scholar
• Mil-Homens D, Leça MI, Fernandes F, et al. Characterization of BCAM0224, a multifunctional trimeric autotransporter from the human pathogen burkholderia cenocepacia. J Bacteriol 2014;196(11):1968-79
   PubMedGoogle Scholar
• Blom AM, Hallström T, Riesbeck K. Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol Immunol 2009;46(14):2808-17
   PubMed Web of Science ®Google Scholar
• Berggård K, Johnsson E, Mooi FR, Lindahl G. Bordetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin. Infect Immun 1997;65(9):3638-43
   PubMed Web of Science ®Google Scholar
• Berggård K, Lindahl G, Dahlbäck B, Blom AM. Bordetella pertussis binds to human C4b-binding protein (C4BP) at a site similar to that used by the natural ligand C4b. Eur J Immunol 2001;31(9):2771-80
   PubMedGoogle Scholar
• Marr N, Luu RA, Fernandez RC. Bordetella pertussis binds human C1 esterase inhibitor during the virulent phase, to evade complement-mediated killing. J Infect Dis 2007;195(4):585-8
   PubMedGoogle Scholar
• Davis AE 3rd, Lu F, Mejia P. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 2010;104(5):886-93
   PubMed Web of Science ®Google Scholar
• Meri T, Amdahl H, Lehtinen MJ, et al. Microbes bind complement inhibitor factor H via a common site. PLoS Pathog 2013;9(4):e1003308
   PubMed Web of Science ®Google Scholar
• Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 2012;14(3):CD001478
   Google Scholar
• Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334(6):349-55
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003;21(17-18):2003-14
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatr Infect Dis J 1997;16(5):508-17
   PubMedGoogle Scholar
• Miller E. Overview of recent clinical trials of acellular pertussis vaccines. Biologicals 1999;27(2):79-86
   PubMedGoogle Scholar
• Stefanelli P, Ippoliti R, Fazio C, Mastrantonio P. Role of immune sera in the in-vitro phagocytosis of Bordetella pertussis strains. Microb Pathog 2002;32(3):135-41
   PubMedGoogle Scholar
• Weingart CL, Keitel WA, Edwards KM, Weiss AA. Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infect Immun 2000;68(12):7175-9
   PubMed Web of Science ®Google Scholar
• Weiss AA, Patton AK, Millen SH, et al. Acellular pertussis vaccines and complement killing of Bordetella pertussis. Infect Immun 2004;72(12):7346-51
   PubMedGoogle Scholar
• Aase A, Herstad TK, Merino S, et al. Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity. Clin Vaccine Immunol 2011;18(8):1269-74
   PubMedGoogle Scholar
• Hellwig SM, Rodriguez ME, Berbers GA, et al. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis 2003;188(5):738-42
   PubMed Web of Science ®Google Scholar
• Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998;16(20):1901-6
   PubMed Web of Science ®Google Scholar
• Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998;16(20):1907-16
   PubMed Web of Science ®Google Scholar
• Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA 2014;111(2):787-92
   PubMed Web of Science ®Google Scholar
• Gotto JW, Eckhardt T, Reilly PA, et al. Biochemical and immunological properties of two forms of pertactin, the 69,000-molecular-weight outer membrane protein of Bordetella pertussis. Infect Immun 1993;61(5):2211-15
   PubMed Web of Science ®Google Scholar
• Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med 2013;368(6):583-4
   PubMedGoogle Scholar
• Lam C, Octavia S, Ricafort L, et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis 2014;20(4):626-33
   PubMed Web of Science ®Google Scholar
• Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol 2014;21(2):119-25
   PubMed Web of Science ®Google Scholar
• Watford WT, Ghio AJ, Wright JR. Complement-mediated host defense in the lung. Am J Physiol Lung Cell Mol Physiol 2000;279(5):L790-8
   PubMed Web of Science ®Google Scholar
• Bolger MS, Ross DS, Jiang H, et al. Complement levels and activity in the normal and LPS-injured lung. Am J Physiol Lung Cell Mol Physiol 2007;292(3):L748-59
   PubMed Web of Science ®Google Scholar
• Marr N, Novikov A, Hajjar AM, et al. Variability in the lipooligosaccharide structure and endotoxicity among Bordetella pertussis strains. J Infect Dis 2010;202(12):1897-906
   PubMed Web of Science ®Google Scholar
• Trollfors B, Lagergård T, Taranger J, et al. Serum immunoglobulin G antibody responses to Bordetella pertussis lipooligosaccharide and B. parapertussis lipopolysaccharide in children with pertussis and parapertussis. Clin Diagn Lab Immunol 2001;8(5):1015-17
   PubMedGoogle Scholar
• Archambault D, Rondeau P, Martin D, Brodeur BR. Characterization and comparative bactericidal activity of monoclonal antibodies to Bordetella pertussis lipo-oligosaccharide A. J Gen Microbiol 1991;137(4):905-11
   PubMedGoogle Scholar
• Mountzouros KT, Kimura A, Cowell JL. A bactericidal monoclonal antibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis. Infect Immun 1992;60(12):5316-18
   PubMed Web of Science ®Google Scholar
• Kubler-Kielb J, Vinogradov E, Lagergård T, et al. Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine. Proc Natl Acad Sci USA 2011;108(10):4087-92
   PubMed Web of Science ®Google Scholar
• Alvarez Hayes J, Erben E, Lamberti Y, et al. Identification of a new protective antigen of Bordetella pertussis. Vaccine 2011;29(47):8731-9
   PubMed Web of Science ®Google Scholar
• Alvarez Hayes J, Erben E, Lamberti Y, et al. Bordetella pertussis iron regulated proteins as potential vaccine components. Vaccine 2013;31(35):3543-8
   PubMedGoogle Scholar
• Marr N, Oliver DC, Laurent V, et al. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 2008;26(34):4306-11
   PubMed Web of Science ®Google Scholar
• Oliver DC, Fernandez RC. Antibodies to BrkA augment killing of Bordetella pertussis. Vaccine 2001;20(1-2):235-41
   PubMed Web of Science ®Google Scholar
• Alonzo F 3rd, Torres VJ. The bicomponent pore-forming leucocidins of Staphylococcus aureus. Microbiol Mol Biol Rev 2014;78(2):199-230
   PubMed Web of Science ®Google Scholar
• Carbonetti NH. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol 2010;5(3):455-69
   PubMed Web of Science ®Google Scholar
• Weingart CL, Mobberley-Schuman PS, Hewlett EL, et al. Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils. Infect Immun 2000;68(12):7152-5
   PubMedGoogle Scholar
• Mills KH, Ross PJ, Allen AC, Wilk MM. Do we need a new vaccine to control the re-emergence of pertussis? Trends Microbiol 2014;22(2):49-52
   PubMedGoogle Scholar
• Buboltz AM, Nicholson TL, Karanikas AT, et al. Evidence for horizontal gene transfer of two antigenically distinct O antigens in Bordetella bronchiseptica. Infect Immun 2009;77(8):3249-57
   PubMedGoogle Scholar
• Vinogradov E, King JD, Pathak AK, et al. Antigenic Variation among Bordetella: bordetella bronchiseptica strain MO149 expresses a novel o chain that is poorly immunogenic. J Biol Chem 2010;285(35):26869-77
   PubMedGoogle Scholar